Trial Profile
A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Allo 501 (Primary) ; ALLO 647; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms ALPHA
- Sponsors Allogene Therapeutics
- 12 Dec 2023 Results (n=87) an analysis assessing safety data of ALLO-647 in patients with r/r LBCL and follicular lymphoma (FL) from two clinical studies: ALPHA and ALPHA2 presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Dec 2023 Results present in the Allogene Therapeutics Media Release.
- 09 Dec 2023 According to an Allogene Therapeutics media release, data from a comprehensive safety review of patients treated in the Phase 1 ALPHA/ALPHA2 trials with ALLO-501/501A will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.